| RLGYX | RWICX | RLGYX / RWICX | |
| Total Expense Ratio | 0.78 | 1.06 | 74% |
| Annual Report Gross Expense Ratio | 0.81 | 1.06 | 76% |
| Fund Existence | 17 years | 24 years | - |
| Gain YTD | 12.777 | 14.126 | 90% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 10000000 | 250 | 4,000,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 3.11B | 142B | 2% |
| Annual Yield % from dividends | 1.02 | 1.11 | 92% |
| Returns for 1 year | 10.66 | 12.08 | 88% |
| Returns for 3 years | 50.97 | 44.85 | 114% |
| Returns for 5 years | 44.22 | 29.60 | 149% |
| Returns for 10 years | 16.29 | 71.36 | 23% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SEMI | 31.04 | 0.11 | +0.35% |
| Columbia Select Technology ETF | |||
| FDTX | 41.28 | 0.04 | +0.10% |
| Fidelity Disruptive Technology ETF | |||
| VCIT | 83.97 | 0.07 | +0.08% |
| Vanguard Interm-Term Corp Bd ETF | |||
| JANU | 28.51 | 0.02 | +0.07% |
| AllianzIM U.S. Equity Buffer15 Uncapped Jan ETF | |||
| IHE | 86.15 | -0.06 | -0.07% |
| iShares US Pharmaceuticals ETF | |||